,text_description,target_label
0,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.057293102,0
1,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 1.0; tumor size 1.937759103,0
2,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.556998315845983,0
3,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.768022772,0
4,race Black or Asia; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.686601401,0
5,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.143665794,0
6,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.95917109,0
7,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.410546541,0
8,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.11179364,0
9,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.050060998,0
10,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.040813309,0
11,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.174537807,1
12,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.07747772,0
13,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.596482328,0
14,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 2.164545056,0
15,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.947381203,0
16,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.033840957,0
17,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.089585527,0
18,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.728400736,0
19,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.992706404,0
20,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.998632049,0
21,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 3.562590498,0
22,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.71994837,0
23,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.79598145,0
24,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.556998315845983,1
25,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.913363463,0
26,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; sentinel node biospy; axillary dissection; number of positive axillary nodes 4.0; tumor size 1.869727389,0
27,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
28,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 3.615383583,0
29,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.783647222,0
30,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.087751375,0
31,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.049962048,0
32,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.149042887,0
33,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.943860404,0
34,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.98611538,0
35,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.510205465,0
36,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.595324922,0
37,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.556998315845983,0
38,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.108335974,1
39,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 1.0; tumor size 1.946257472,0
40,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.062016844,0
41,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 3.798079464,0
42,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.55793838,1
43,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
44,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
45,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.72567596,1
46,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.087172191,0
47,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.083358289,1
48,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.655283529,0
49,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.596543334,0
50,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; axillary dissection; number of positive axillary nodes 4.0; tumor size 2.017307041,0
51,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.645571354,0
52,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.843653774,0
53,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.352930517,0
54,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.191503354,0
55,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.99798799,1
56,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality bilateral; estrogen receptor positive; cancer histologic grade Intermediate; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.870697961,1
57,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.056830908,1
58,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.142868411,0
59,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality bilateral; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.44563001,0
60,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.966771835,0
61,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.66960444,0
62,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Low; biopsy type; number of positive axillary nodes 0.0; tumor size 2.051727693,0
63,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.90484093,0
64,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.904375625,0
65,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
66,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality bilateral; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.231394303,0
67,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.008791031,0
68,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.884151342,0
69,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.081346946,0
70,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.090358923,0
71,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.848325026,0
72,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 3.526141947,0
73,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.256385406,0
74,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.333782098,0
75,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 1.0; tumor size 3.81975543,0
76,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
77,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.46920542,0
78,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.926084108,0
79,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.850185927,0
80,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
81,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.16263112,0
82,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.663000952,0
83,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.982223937,0
84,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.369228629,0
85,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.959296732,0
86,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
87,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.385700647,0
88,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 0.161217587373168; tumor size 1.72777183,1
89,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.079707745,0
90,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.898371311,0
91,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.942159979,0
92,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.540375441,1
93,race Black or Asia; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.83012964,0
94,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
95,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.06506638,1
96,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.150075383,0
97,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.387144146,0
98,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.180308248,0
99,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
100,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.073995779,0
101,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; number of positive axillary nodes 0.0; tumor size 2.041023904,0
102,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 2.059619547,1
103,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.582922032,0
104,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.776728313,0
105,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; biopsy type; number of positive axillary nodes 0.0; tumor size 3.667125425,0
106,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 3.459012477,1
107,race Black or Asia; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.801652816,0
108,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.974328317,1
109,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.970868846,0
110,race Black or Asia; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 5.093794843,0
111,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.998899719,0
112,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 2.173218449,0
113,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.138269318,0
114,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
115,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; number of positive axillary nodes 1.0; tumor size 2.556998315845983,0
116,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.59099002,0
117,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 2.02926905,0
118,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; number of positive axillary nodes 0.0; tumor size 2.189659241,0
119,race Black or Asia; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.227067547,0
120,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
121,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.422797116,0
122,race Black or Asia; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.393198079,0
123,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.97819105,0
124,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.366956927,0
125,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.079499325,0
126,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.959919789,0
127,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
128,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 3.525874551,0
129,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; axillary dissection; number of positive axillary nodes 1.0; tumor size 1.765956476,0
130,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 1.988084827,0
131,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.194049305,0
132,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.425306047,0
133,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.917675455,0
134,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.273845451,0
135,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality bilateral; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.504221124,0
136,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 3.475271301,0
137,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.933338018,0
138,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
139,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.043902414,0
140,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 1.0; tumor size 3.496316019,0
141,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.867222262,0
142,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.46292291,1
143,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.663136037,0
144,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.161217587373168; tumor size 3.447863592,0
145,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.915812913,0
146,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.949678667,0
147,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
148,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 1.577008635,0
149,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.053336787,0
150,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
151,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.188245063,0
152,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.48823579,0
153,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.947623468,0
154,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.129398298,1
155,race Black or Asia; treatment Trastuzumab; tumor laterality right; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.152776391,0
156,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.208853302,0
157,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.0450262,0
158,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 2.179803092,1
159,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.506075096,0
160,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.377139431,0
161,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.627239982,1
162,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.160003589,0
163,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.498248205,0
164,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
165,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.035414117,1
166,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 2.219091096,0
167,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.552829168,0
168,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 5.024384401,0
169,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.792535609,0
170,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.016698526,0
171,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.66072514,0
172,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.028971246,0
173,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.525592088,0
174,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.143254804,0
175,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.33409884,0
176,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.865764487,0
177,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
178,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality bilateral; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.055474099,0
179,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.88655324,0
180,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.524398544,0
181,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 3.530993087,0
182,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.842837442,0
183,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.484979263,0
184,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
185,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.789577428,0
186,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
187,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.596112466,0
188,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.482019029,0
189,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.935685122,0
190,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.008119345,0
191,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.057334351,1
192,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
193,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.972968602,0
194,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; number of positive axillary nodes 0.0; tumor size 1.784762017,0
195,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.148239092,0
196,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.099421359,0
197,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.205937938,0
198,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.675640948,0
199,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 2.029987489,0
200,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.853721494,1
201,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 2.0; tumor size 1.81583367,0
202,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
203,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; biopsy type; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.291514711,0
204,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.422639793,1
205,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.695726584,0
206,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 1.872698131,1
207,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.140723443,0
208,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.488084765,0
209,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.433891584,0
210,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.964462731,0
211,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.161217587373168; tumor size 2.088520215,0
212,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.727290198,0
213,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.835545407,0
214,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.558158383,0
215,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
216,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.066569388,0
217,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.252504926,0
218,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.309536614,0
219,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
220,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 1.861422626,0
221,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 3.0; tumor size 3.564306405,0
222,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.015998747,0
223,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.486850172,0
224,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 3.0; tumor size 2.038646826,1
225,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.526661791,1
226,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
227,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.729441788,0
228,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.896714948,1
229,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 3.772275804,0
230,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.392100622,0
231,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.408443132,1
232,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.010591497,0
233,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.170310398,0
234,race Black or Asia; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.774579619,0
235,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
236,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
237,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.309284566,0
238,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.880816617,0
239,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.490784339,0
240,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.981499524,0
241,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 2.170270802,1
242,race Black or Asia; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.676526935,0
243,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.914655417,0
244,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.492887447,0
245,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.435003125,0
246,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.491036775,0
247,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
248,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.767668079,0
249,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.065984006,0
250,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
251,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.947650113,0
252,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.863661026,0
253,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.383511415,0
254,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.808385241,0
255,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.862759395,0
256,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
257,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.403206334,0
258,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.441926818,0
259,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.335067039,0
260,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 3.403013905,0
261,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 1.0; tumor size 3.460971782,0
262,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.010862816,0
263,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
264,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 2.037301808,0
265,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; biopsy type; number of positive axillary nodes 0.0; tumor size 3.249670477,0
266,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.735041603,0
267,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.757729027,0
268,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.814403942,0
269,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.516789823,0
270,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.312577049,0
271,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.628180302,1
272,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.040845419,0
273,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.063285327,0
274,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 3.468875651,1
275,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.935017222,0
276,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.763859086,1
277,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.894670524,1
278,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.762295414,0
279,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 2.032915486,0
280,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.038839043,0
281,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.680232651,0
282,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.846930653,0
283,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.004711279,0
284,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.242672011,0
285,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.086168956,1
286,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.161217587373168; tumor size 2.046400052,1
287,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.556998315845983,0
288,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.913169251,0
289,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.660121223,0
290,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.819990904,0
291,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 1.835862813,0
292,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 3.5600995,0
293,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
294,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.545891119,0
295,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.999789395,0
296,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.542763855,0
297,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.246865171,0
298,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.648107307,0
299,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
300,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.164527046,0
301,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
302,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.120725189,0
303,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.029715493,0
304,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.480321995,0
305,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.055697148,0
306,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.045093649,0
307,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.370031167,0
308,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 1.893455196,1
309,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.000403604,0
310,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.023384901,0
311,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.196918271,0
312,race Black or Asia; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
313,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.987904941,0
314,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
315,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.412932136,1
316,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.470537361,0
317,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.697461781,0
318,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; number of positive axillary nodes 0.161217587373168; tumor size 2.076547145,0
319,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 2.0; tumor size 3.430946014,1
320,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.884684245,0
321,race White; treatment Trastuzumab; tumor laterality bilateral; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.814334194,1
322,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade Low; biopsy type; number of positive axillary nodes 0.0; tumor size 2.163475787,0
323,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.705807514,0
324,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality bilateral; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.092020243,0
325,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.167718236,0
326,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
327,race Black or Asia; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.861953006,0
328,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.701355886,1
329,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.103512749,0
330,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.045008325,0
331,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.914523241,0
332,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.459774733,0
333,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 2.556998315845983,0
334,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.700647448,0
335,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; number of positive axillary nodes 2.0; tumor size 1.909344259,0
336,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
337,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.567068168,0
338,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.910138077,0
339,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.98367387,1
340,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.02563421,0
341,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.556998315845983,0
342,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 3.443499216,0
343,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 5.200802285,0
344,race Black or Asia; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.002167103,0
345,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 2.027762804,1
346,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.976436083,0
347,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 3.621998344,0
348,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
349,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 3.0; tumor size 3.56117208,1
350,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.753529321,0
351,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.934280624,0
352,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 3.543754517,0
353,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.958902937,0
354,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.592478537,0
355,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.556998315845983,0
356,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 4.693219627,0
357,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.722977409,0
358,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.015231796,0
359,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.614366372,0
360,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
361,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.458862664,0
362,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.067268781,0
363,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 3.0; tumor size 3.66896752,1
364,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.129820883,0
365,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.374607319,0
366,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Low; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.913124226,0
367,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.217930702,0
368,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.624952588,0
369,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.310853257,0
370,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.263380898,0
371,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.26417433,0
372,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.948865254,0
373,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 3.395806302,0
374,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.676519302,0
375,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.983579588,0
376,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.006017996,0
377,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
378,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.512354367,0
379,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.752812762,1
380,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.917389442,0
381,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.367212241,1
382,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.194202948,0
383,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.599988644,0
384,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.588319472,1
385,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.771550629,1
386,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 1.885771787,0
387,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.045618918,0
388,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.778509093,0
389,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.516811102,0
390,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
391,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.896215044,0
392,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.106786999,0
393,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
394,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; biopsy type; axillary dissection; number of positive axillary nodes 2.0; tumor size 2.03058709,1
395,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.878573434,0
396,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.127262332,0
397,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.68372206,1
398,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
399,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.431811626,0
400,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.67667839,0
401,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.334071758,0
402,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.575258395,0
403,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.824817407,0
404,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
405,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
406,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.193972352,0
407,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.098810081,0
408,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.111570724,0
409,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.173131745,0
410,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.388441378,0
411,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 1.8891448,0
412,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 2.002520771,0
413,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.563802082,1
414,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.317195189,0
415,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.560305596,0
416,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.874250334,0
417,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.332169711,0
418,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.810390484,0
419,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 3.376826122,0
420,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.134958314,1
421,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.071390262,0
422,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.442490384,0
423,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
424,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.474499504,0
425,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.244408204,0
426,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.843966898,0
427,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.068000234,0
428,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.161217587373168; tumor size 1.859395535,0
429,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.936036352,0
430,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.849560614,0
431,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; number of positive axillary nodes 0.161217587373168; tumor size 3.46549693,1
432,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.628635282,1
433,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
434,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
435,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.805380042,0
436,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.023324588,0
437,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 2.046309479,0
438,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.215488032,0
439,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.503486386,1
440,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.896016855,0
441,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.611198203,0
442,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.078854549,0
443,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.066903294,0
444,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 3.596719875,0
445,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.879979862,0
446,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality bilateral; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.359052778,0
447,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.253894977,0
448,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.153979881,0
449,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.05962453,0
450,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.412315954,1
451,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.161217587373168; tumor size 2.556998315845983,0
452,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
453,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.107058098,0
454,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
455,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.01906633,0
456,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.876105638,0
457,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.639747684,0
458,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.189296817,0
459,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.819576704,1
460,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.068249494,0
461,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 1.0; tumor size 1.89118466,1
462,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality bilateral; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.414915819,0
463,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
464,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.336344034,0
465,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.186723494,0
466,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 3.701558222,0
467,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.81148508,0
468,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.995746471,0
469,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.258705913,0
470,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.444363551,0
471,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.499796863,0
472,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.73510686,0
473,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
474,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.726160162,0
475,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.739514021,0
476,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.048484854,0
477,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.936855947,0
478,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.946776833,0
479,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.466877407,1
480,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.300897324,0
481,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.036420582,1
482,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.500561953,0
483,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 3.630597312,0
484,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.438003799,0
485,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.14336748,1
486,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.600535489,0
487,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.790492704,0
488,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 4.0; tumor size 3.439196763,0
489,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.129225989,1
490,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 3.57984723,0
491,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 2.27789167,0
492,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.295162472,1
493,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.7036541,1
494,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.019791282,0
495,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.600864989,0
496,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.541371709,0
497,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
498,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.455254545,1
499,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.848952477,0
500,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.564213684,0
501,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; biopsy type; number of positive axillary nodes 0.0; tumor size 3.346071002,0
502,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.924201172,0
503,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 3.590442681,0
504,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.42130737,1
505,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 1.904943158,0
506,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 5.045293218,0
507,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.855303724,0
508,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.598081932,0
509,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; number of positive axillary nodes 0.161217587373168; tumor size 3.417878141,1
510,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 2.0; tumor size 3.311169751,1
511,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 3.0; tumor size 2.189974706,0
512,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.161217587373168; tumor size 2.01686673,0
513,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.505973134,0
514,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 4.0; tumor size 2.112615734,0
515,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.101860192,0
516,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 2.0; tumor size 3.657484963,0
517,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.481015792,0
518,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.239274195,0
519,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 1.0; tumor size 1.91642333,0
520,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 3.460753234,0
521,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.544629463,0
522,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.081557786,0
523,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.08468062,0
524,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.764797091,1
525,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.327876014,0
526,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.619229353,0
527,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.444559206,0
528,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.085520366,0
529,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
530,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.146354858,0
531,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.847115219,1
532,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
533,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.260951277,0
534,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.65527107,0
535,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
536,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 4.854208567,0
537,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.02053251,0
538,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 1.976820611,0
539,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.981419896,0
540,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.567527286,0
541,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.140893925,0
542,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality bilateral; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
543,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
544,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 1.0; tumor size 3.306064356,1
545,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.111593816,1
546,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.392178936,0
547,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.223824036,0
548,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.981891827,0
549,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.136563125,0
550,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.047702938,0
551,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.997497408,0
552,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.260610985,0
553,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.035645665,1
554,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.787851279,0
555,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.747937832,0
556,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.594938439,0
557,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.900954246,0
558,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality bilateral; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.19436867,0
559,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.572768016,0
560,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.08418726,0
561,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.318684314,0
562,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
563,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.776511262,0
564,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.796035425,0
565,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 3.403229039,0
566,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.042815705,0
567,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.384020043,0
568,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 3.144762927,1
569,race Black or Asia; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.116129998,0
570,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.149124827,0
571,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.904633412,0
572,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.417561751,0
573,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
574,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.963027209,0
575,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.24435128,0
576,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.4853197,0
577,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.918000376,1
578,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.044853173,0
579,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.033924352,0
580,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.076227758,1
581,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.826828161,0
582,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.946179011,0
583,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 4.011534976,0
584,race Black or Asia; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.099063283,0
585,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.037486841,1
586,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.136253223,0
587,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
588,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.103692111,1
589,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.603893701,0
590,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.084070527,0
591,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.851468571,0
592,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
593,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.567181341,0
594,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.901635738,0
595,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.123048816,0
596,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.975994483,0
597,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.538897136,0
598,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 3.413679709,0
599,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.278031362,0
600,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.428607391,1
601,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.079573896,0
602,race White; post-menopause; treatment Trastuzumab; tumor laterality bilateral; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.519537315,0
603,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 2.125618495,0
604,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.207549788,0
605,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
606,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.057383574,1
607,race Black or Asia; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.047835663,0
608,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
609,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 4.643829566,0
610,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 1.0; tumor size 5.015136791,0
611,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.616334443,0
612,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
613,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.287924397,1
614,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.132230334,0
615,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality bilateral; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.972571972,0
616,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 2.27369937,0
617,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.4036025,0
618,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 1.945651316,0
619,race Black or Asia; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.156563883,0
620,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.035273659,0
621,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.800744037,0
622,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.697150911,0
623,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.439309631,0
624,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.964213761,1
625,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.553453322,1
626,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.963008824,0
627,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.028785452,1
628,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.903323741,0
629,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.141818147,0
630,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.63005528,0
631,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.981739598,0
632,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.860601335,1
633,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.698339757,0
634,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 2.046904262,0
635,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.99491049,0
636,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.365694377,0
637,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.071396465,0
638,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 1.766665981,0
639,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.891866859,0
640,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.086631347,1
641,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 1.0; tumor size 1.791724298,1
642,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.613610318,1
643,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.425784708,0
644,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.935504711,0
645,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.919195224,1
646,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.420668729,0
647,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.196719817,0
648,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.224751804,1
649,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.31612772,0
650,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 1.0; tumor size 2.190602597,0
651,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.221307224,1
652,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 3.0; tumor size 2.308530987,0
653,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.026842066,0
654,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 2.556998315845983,0
655,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
656,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.993164448,0
657,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.08576779,0
658,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.337517123,0
659,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.953829781,0
660,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.825570232,0
661,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.848019071,0
662,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.57167381,0
663,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.31016744,0
664,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.898042773,0
665,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.890276826,0
666,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.334253068,0
667,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.427588871,0
668,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.035865772,0
669,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality bilateral; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.953140784,1
670,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
671,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.053518555,0
672,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.323106997,0
673,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.015639467,0
674,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.717426303,1
675,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 2.158919917,0
676,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.000696945,0
677,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.686767029,0
678,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
679,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
680,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 2.0; tumor size 3.823260718,0
681,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.809845575,1
682,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.193359508,0
683,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.126774603,0
684,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.497734598,1
685,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.356849538,0
686,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.91455962,0
687,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.45860516,0
688,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.321010924,0
689,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 3.0; tumor size 3.291746565,0
690,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.456415041,0
691,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.162173593,0
692,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 3.512458433,0
693,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.108712703,0
694,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.866072414,0
695,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.857325652,0
696,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.792815952,0
697,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.889369499,0
698,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.34077666,0
699,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.478249354,0
700,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.465462196,0
701,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.399585797,0
702,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.950448268,1
703,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.874427874,0
704,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.863217194,0
705,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
706,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.138182784,0
707,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.033713354,0
708,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.301443986,0
709,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.445877742,0
710,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.116773316,0
711,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 3.0; tumor size 3.464565423,0
712,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 1.999321317,0
713,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
714,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.993032811,0
715,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 1.815822179,0
716,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
717,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
718,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.928951363,0
719,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.372168066,0
720,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.537903335,1
721,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.059211323,0
722,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.768343358,1
723,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.373123039,0
724,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.952309821,1
725,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.070616291,1
726,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.818955232,0
727,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.013077916,0
728,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.190947982,0
729,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.608608789,1
730,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.406390217,0
731,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 3.763237373,0
732,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.091889888,0
733,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.301842704,0
734,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.915294378,1
735,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 1.769097523,0
736,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.288135148,0
737,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.121126773,0
738,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.642450117,1
739,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.597876975,0
740,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 4.916566276,0
741,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.999395234,0
742,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.5197498,0
743,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.676289482,1
744,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 1.879848512,0
745,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.038546006,0
746,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.442465306,0
747,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 1.0; tumor size 3.331568808,0
748,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.893916258,0
749,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.277008,0
750,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 1.0; tumor size 1.932364201,0
751,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.991524733,1
752,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.743169623,0
753,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
754,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.924226799,0
755,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.4763022,1
756,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.990751112,0
757,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.722937282,0
758,race White; post-menopause; treatment Trastuzumab; tumor laterality bilateral; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 3.338650582,0
759,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.255335579,0
760,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.848681279,0
761,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.123004168,0
762,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
763,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.409540781,0
764,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.007918795,1
765,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.028799887,0
766,race Black or Asia; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.683952761,0
767,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 2.0; tumor size 2.556998315845983,0
768,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality bilateral; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.106124884,0
769,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.00363404,0
770,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 1.0; tumor size 4.920884296,1
771,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; number of positive axillary nodes 0.0; tumor size 1.794105349,0
772,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 3.50035855,1
773,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality bilateral; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.063396236,1
774,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.621454448,0
775,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 3.195931021,0
776,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
777,race Black or Asia; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.504637198,0
778,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 3.584435088,1
779,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 2.0; tumor size 1.979353226,0
780,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.072314967,0
781,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.113010527,1
782,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.049441943,0
783,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.895472961,1
784,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.017049713,1
785,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.924311329,0
786,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
787,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.963213799,0
788,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.818505803,0
789,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.381964741,0
790,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.749723793,0
791,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.037084849,0
792,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.880059782,0
793,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.586613647,0
794,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.040125251,0
795,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.76974628,0
796,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.78611817,0
797,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.920906254,0
798,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.89613964,0
799,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.675280974,0
800,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.124383906,0
801,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.157379405,0
802,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.962436839,0
803,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.02931304,1
804,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; number of positive axillary nodes 2.0; tumor size 1.939629139,0
805,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 2.016506959,0
806,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.619882701,0
807,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 3.572549271,0
808,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.524120137,0
809,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.190102198,0
810,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.683401932,0
811,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.843577255,0
812,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.911281358,0
813,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.396206587,0
814,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.236270204,0
815,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.812445807,1
816,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.29543779,0
817,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.893258477,0
818,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.886020488,0
819,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
820,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.973993595,0
821,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 1.927202558,1
822,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.08972687,0
823,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; biopsy type; number of positive axillary nodes 0.0; tumor size 3.479647758,0
824,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.557588973,0
825,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.299971246,1
826,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.882575551,0
827,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 3.646357962,0
828,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.026987682,1
829,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.81905511,1
830,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 2.244428194,0
831,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.960146871,0
832,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.139471287,0
833,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.245772348,0
834,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.177224051,1
835,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.161217587373168; tumor size 2.556998315845983,0
836,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.953400374,0
837,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.134424553,1
838,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.87873808,0
839,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 1.721271499,0
840,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.079540401,0
841,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.057334846,0
842,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 1.963354979,0
843,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.957484209,0
844,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.053027052,0
845,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.910122205,0
846,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.081381068,0
847,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.975758651,0
848,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 1.0; tumor size 1.811782075,0
849,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.440406064,0
850,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.989822883,0
851,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.414589442,0
852,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 1.960709173,0
853,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 1.0; tumor size 3.519630572,0
854,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.121864136,0
855,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.087437832,0
856,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 3.766266036,0
857,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
858,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.783884435,0
859,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.157610174,0
860,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.161217587373168; tumor size 2.048215801,0
861,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 3.534358256,0
862,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.006277887,0
863,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.014894411,0
864,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 1.857522663,0
865,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.886107604,1
866,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.96025778,0
867,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.168635212,0
868,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.003400668,0
869,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.84493493,0
870,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.533197984,0
871,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; biopsy type; number of positive axillary nodes 0.0; tumor size 1.804939465,0
872,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.823267467,1
873,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
874,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.324961343,0
875,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.731358483,0
876,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.850628963,0
877,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 1.0; tumor size 1.792847286,0
878,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.126946736,0
879,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.417510206,1
880,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 2.0; tumor size 2.39375006,0
881,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.556998315845983,0
882,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.090654742,0
883,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.170371599,0
884,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.703669313,0
885,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.862807045,0
886,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
887,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; number of positive axillary nodes 0.161217587373168; tumor size 2.072587998,0
888,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.067161811,0
889,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.930004312,0
890,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.941311157,0
891,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.036160508,0
892,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.596560245,1
893,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.755769963,0
894,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.9498045,1
895,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.732996053,0
896,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.96953285,0
897,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 1.973816207,0
898,race Black or Asia; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.161217587373168; tumor size 2.054661708,1
899,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.079949819,0
900,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 4.906554024,0
901,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.40224461,1
902,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.089396722,0
903,race White; post-menopause; treatment Trastuzumab; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.08503649,0
904,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.530809024,0
905,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.786053638,0
906,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.1203028,0
907,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.504736816,0
908,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.54797002,0
909,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.149822267,0
910,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.187404601,0
911,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.842078105,0
912,race Black or Asia; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.025914692,1
913,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 4.0; tumor size 2.556998315845983,0
914,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.510428554,0
915,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.129811299,0
916,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Low; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.060490713,0
917,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 2.04452109,0
918,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.938066622,0
919,race White; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 1.840523756,0
920,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.932652565,0
921,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.834850364,0
922,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.698399517,0
923,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 2.0; tumor size 1.918900489,0
924,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Low; number of positive axillary nodes 0.0; tumor size 1.933197781,1
925,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.341490927,0
926,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.718980139,0
927,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; number of positive axillary nodes 0.0; tumor size 1.864002596,0
928,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 4.966589932,0
929,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.016287736,0
930,race White; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.05292431,0
931,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; number of positive axillary nodes 0.0; tumor size 2.556998315845983,1
932,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.079142067,0
933,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.220711223,0
934,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.616550952,0
935,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.947803576,0
936,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 3.297992112,0
937,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.898010562,0
938,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.076069498,0
939,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
940,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.985761055,0
941,race Black or Asia; treatment Trastuzumab; tumor laterality right; cancer histologic grade Low; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.511743756,1
942,race Black or Asia; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 2.060175615,0
943,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 2.0; tumor size 2.038813869,0
944,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Low; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
945,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Low; number of positive axillary nodes 0.0; tumor size 3.618958215,0
946,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.117104556,0
947,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 1.950627847,1
948,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
949,race White; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.765223498,1
950,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
951,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.013418881,0
952,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
953,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 2.0; tumor size 1.97078555,1
954,race White; post-menopause; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.512557894,0
955,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; biopsy type; number of positive axillary nodes 0.0; tumor size 2.145314031,0
956,race Black or Asia; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 2.0; tumor size 3.578696674,0
957,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.112516976,0
958,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.582932276,1
959,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Low; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 3.90430094,1
960,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.518915748,0
961,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.737981242,0
962,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.985862522,1
963,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.662858946,0
964,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 2.059789887,0
965,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.161217587373168; tumor size 3.213051263,0
966,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.075879121,0
967,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.034176031,0
968,race White; treatment Trastuzumab; tumor laterality left; cancer histologic grade High; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.512905021,1
969,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.62787484,0
970,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Low; prior chemotherapy; number of positive axillary nodes 0.161217587373168; tumor size 1.996210446,0
971,race White; post-menopause; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 1.0; tumor size 1.985672519,0
972,race White; post-menopause; treatment Trastuzumab; tumor laterality right; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 3.349868872,0
973,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.823278743,0
974,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality bilateral; progesterone receptor positive; cancer histologic grade Low; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 3.243817078,0
975,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.607741313,0
976,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; biopsy type; number of positive axillary nodes 0.0; tumor size 3.30829396,1
977,race White; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; number of positive axillary nodes 0.0; tumor size 1.98685608,0
978,race Black or Asia; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade Intermediate; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.132989926,0
979,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 1.999902792,1
980,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.550440474,0
981,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
982,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
983,race White; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.13199289,0
984,race White; treatment Trastuzumab; tumor laterality right; estrogen receptor positive; cancer histologic grade Intermediate; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 2.116681701,0
985,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; progesterone receptor positive; cancer histologic grade Low; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.426982004,0
986,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 2.0; tumor size 3.568407564,0
987,race White; post-menopause; treatment Trastuzumab; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.474386028,1
988,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.161217587373168; tumor size 3.523301426,1
989,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.556998315845983,0
990,race White; human epidermal growth factor receptor 2 is positive; treatment Trastuzumab; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.161217587373168; tumor size 2.041144269,0
991,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 2.12789367,0
992,race White; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade High; prior chemotherapy; sentinel node biospy; number of positive axillary nodes 0.0; tumor size 2.084439407,0
993,race White; post-menopause; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; progesterone receptor positive; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 0.0; tumor size 3.419783443,1
994,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; progesterone receptor positive; cancer histologic grade Intermediate; number of positive axillary nodes 0.0; tumor size 3.258830201,0
995,race White; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior chemotherapy; biopsy type; axillary dissection; number of positive axillary nodes 0.0; tumor size 1.98219071,1
996,race White; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; cancer histologic grade Intermediate; prior hormonal therapy; prior chemotherapy; biopsy type; sentinel node biospy; axillary dissection; number of positive axillary nodes 1.0; tumor size 3.670038197,0
997,race Black or Asia; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; biopsy type; sentinel node biospy; number of positive axillary nodes 2.0; tumor size 3.713288761,0
998,race Black or Asia; post-menopause; human epidermal growth factor receptor 2 is positive; treatment Cyclophosphamide and Doxorubicin; tumor laterality right; estrogen receptor positive; cancer histologic grade High; prior hormonal therapy; number of positive axillary nodes 0.0; tumor size 3.299946515,1
999,race Black or Asia; post-menopause; treatment Trastuzumab; tumor laterality left; estrogen receptor positive; progesterone receptor positive; cancer histologic grade High; prior hormonal therapy; prior chemotherapy; biopsy type; number of positive axillary nodes 0.0; tumor size 3.486930181,1
